Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.
Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy.
Crit Rev Oncol Hematol. 2018 Sep;129:40-43. doi: 10.1016/j.critrevonc.2018.06.006. Epub 2018 Jun 18.
Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.
尽管治疗策略有所不同，但局部晚期宫颈癌（CC）仍然是全球女性中最难治愈的癌症之一。事实上，这类患者存在持续性和复发性疾病的高风险。近年来，研究人员研究了免疫检查点抑制剂，以期确定改善对治疗的反应并延长生存时间。我们回顾了已发表的文献和会议记录，并介绍了支持免疫检查点抑制剂在 CC 治疗中的关键试验。
